Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8261338 | 0.86 | POLB (0.45) | KMT2AMEN1SMN1; SMN2ALDH1A1GLA | |
| SCHEMBL13993710 | 0.81 | CCNA2 (0.43) | GPR6CCNA2CDK2MAPK1 | |
| SCHEMBL13993720 | 0.81 | CCNA2 (0.43) | GPR6POLBCCNA2CDK2CDK1 | |
| SCHEMBL8261339 | 0.80 | TAS1R3 (0.48) | KMT2AMEN1ALDH1A1POLBTP53 | |
| SCHEMBL5006763 | 0.79 | CDK1 (0.40) | KMT2AMEN1POLBCCNA2CDK2 | |
| SCHEMBL1646081 | 0.79 | GPR35 (0.50) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL2801156 | 0.79 | KMT2A (0.49) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL5007605 | 0.79 | CDK14 (0.46) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL955039 | 0.78 | MEN1 (0.49) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5011543 | 0.78 | CDK14 (0.36) | KMT2AMEN1POLBCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | claimed |
| EP-1846395-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | claimed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | claimed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| EP-1846395-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | KMT2A 108/4885MEN1 4051/4885SMN1; SMN2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.